Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol and melitracen is a combination medication used for the treatment of anxiety and depression. Flupentixol is a thioxanthene antipsychotic, and melitracen is a tricyclic antidepressant.
## Primary Indications
* Anxiety and depression, particularly when accompanied by apathy and fatigue.
## Adult Dosing
* **Typical starting dose:** 1 tablet (0.5 mg flupentixol/10 mg melitracen) twice daily.
* **Maximum dose:** 3 tablets (1.5 mg flupentixol/30 mg melitracen) daily.
* Dose adjustments should be made based on individual patient response and tolerability.
## Pediatric Dosing
* Safety and efficacy in pediatric patients have not been established. Use is not recommended.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary. Specific guidelines are lacking and should be guided by clinical judgment.
* **Renal Impairment:** No specific dose adjustments are routinely recommended, but caution is advised.
## Contraindications
* Hypersensitivity to flupentixol, melitracen, or any excipients.
* Recent myocardial infarction.
* Circulatory collapse.
* Marked depression of the central nervous system.
* Coma.
* Severe liver disease.
* Acute glaucoma.
* Untreated narrow-angle glaucoma.
* Urinary retention.
## Adverse Effects
* **Common:** Drowsiness, dry mouth, blurred vision, constipation, dizziness, headache, fatigue, increased sweating.
* **Less Common/Serious:** Extrapyramidal symptoms (e.g., akathisia, dystonia, parkinsonism), QTc prolongation, orthostatic hypotension, anticholinergic effects, blood dyscrasias, hyponatremia.
## Key Drug Interactions
* **CNS Depressants (alcohol, sedatives, hypnotics, opioids):** Increased CNS depression.
* **MAOIs:** Risk of hypertensive crisis and serotonin syndrome. Avoid concurrent use and a washout period is required.
* **QTc Prolonging Agents:** Increased risk of torsades de pointes.
* **Anticholinergic Agents:** Additive anticholinergic effects.
* **Guanethidine and similar antihypertensives:** Reduced antihypertensive effect.
## Monitoring
* Monitor for signs and symptoms of depression, anxiety, and suicidal ideation.
* Monitor for extrapyramidal symptoms, anticholinergic effects, and orthostatic hypotension.
* Consider baseline and follow-up ECG, especially in patients with cardiac risk factors or concomitant QTc-prolonging medications.
* Monitor liver function if clinically indicated.
## Clinical Pearls
* Combination therapy may offer a broader spectrum of activity for patients with mixed anxiety and depressive symptoms.
* Drowsiness can be significant; advise patients to avoid driving or operating heavy machinery until they know how the medication affects them.
* The therapeutic effect may not be apparent for several weeks.
* Abrupt discontinuation should be avoided. Tapering the dose gradually is recommended.
***
*Please verify the latest prescribing information with current guidelines and product monographs before initiating therapy.*
